Evaluating synergistic versus additive effects of the triplet regimen in metastatic castration-sensitive prostate cancer: a modeling analysis
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Shinro Hata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita 879-5593, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The ARASENS trial demonstrated a significant overall survival (OS) benefit for a triplet regimen in metastatic castration-sensitive prostate cancer (mCSPC). We aimed to determine whether this benefit is synergistic or additive. Using a mathematical model of independent drug action and published data from the ARASENS and ARANOTE, we compared the observed OS of the triplet regimen to a predicted OS curve. Reconstructed individual patient data were compared using a Cox model. The observed OS was statistically superior to the predicted OS (hazard ratio [HR] 0.82, 95% CI 0.68–0.99; P = .047), indicating a clinical benefit ~18% greater than the expected additive effect. To address confounding by subsequent therapies, we analyzed time to initial subsequent anticancer therapy, which showed an even more pronounced greater-than-additive benefit (HR 0.57, 95% CI 0.44–0.74; P < .001). These findings suggest the triplet regimen provides an early therapeutic advantage that exceeds additive expectations, supporting an upfront combination strategy in mCSPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita 879-5593, Japan.
ORCID-Profile: Shinro Hata
Zitieren
APA
Hata, S., Suzuki, S., Fujinami, H., Yamanaka, N., & Shin, T. (2025). Evaluating synergistic versus additive effects of the triplet regimen in metastatic castration-sensitive prostate cancer: a modeling analysis. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf211
Vancouver
Hata S, Suzuki S, Fujinami H, Yamanaka N, Shin T. Evaluating synergistic versus additive effects of the triplet regimen in metastatic castration-sensitive prostate cancer: a modeling analysis. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf211
BibTeX
@article{Hata2025,
author = {Hata, Shinro and Suzuki, Shuntaro and Fujinami, Hiroyuki and Yamanaka, Naoyuki and Shin, Toshitaka},
title = {Evaluating synergistic versus additive effects of the triplet regimen in metastatic castration-sensitive prostate cancer: a modeling analysis},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf211}
}
EUVIMED